Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
30 April to 23 May 2008.
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2008
Report date:
2008

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
Version / remarks:
adopted 17th December 2001
Deviations:
no
Qualifier:
according to guideline
Guideline:
EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
GLP compliance:
yes (incl. QA statement)
Test type:
acute toxic class method
Limit test:
yes

Test material

Constituent 1
Chemical structure
Reference substance name:
Tetrasodium 4,4'-bis[[4-morpholino-6-(p-sulphonatoanilino)-1,3,5-triazin-2-yl]amino]stilbene-2,2'-disulphonate
EC Number:
249-323-0
EC Name:
Tetrasodium 4,4'-bis[[4-morpholino-6-(p-sulphonatoanilino)-1,3,5-triazin-2-yl]amino]stilbene-2,2'-disulphonate
Cas Number:
28950-61-0
Molecular formula:
C40H40-xN12NaxO14S4
IUPAC Name:
tetrasodium 2,2'-ethene-1,2-diylbis[5-({4-morpholin-4-yl-6-[(4-sulfonatophenyl)amino]-1,3,5-triazin-2-yl}amino)benzenesulfonate]
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source and lot/batch number of test material: 0582900
- Expiration date of the lot/batch: 25-FEB-2013

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: At room temperature (range of 20 ± 5 °C, light protected.

Test animals

Species:
rat
Strain:
Wistar
Sex:
female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: RCCLtd Laboratory Animal Services Wölferstrasse 4 4414 Füllinsdorf / Switzerland
- Animals: rat, HanRcc: WIST(SPF).
- Age at study initiation: 11 weeks.
- Housing: in groups of three in Makrolon type-4 cages with wire mesh tops and standard softwood bedding ('Lignocel' Schill AG, CH-4132 Muttenz, Switzerland) .
- Diet: pelleted standard Provimi Kliba 3433 rat/mouse maintenance diet, batch no. 12/08 (Provimi Kliba AG, CH-4303 Kaiseraugst/Switzerland) ad libitum.
- Water: community tap water from Füllinsdorf ad libitum.
- Acclimation period: under laboratory conditions, after health examination. Only animals without any visible signs of illness were used for the study.

ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 3 °C, continuously monitored.
- Humidity: between 30-70 % (values above 70 % during cleaning process possible).
- Air changes: 10-15 air changes per hour.
- Photoperiod: light cycle of 12 hours light and 12 hours dark.
- Other: music during the daytime light period.

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
polyethylene glycol
Remarks:
PEG 300
Details on oral exposure:
VEHICLE
- Vehicle: polyethylene glycol 300 (PEG 300)
- Justification for choice of vehicle: the vehicle was chosen after a non-GLP solubility trial which was performed before the study initiation date. This formulation trial is excluded from the statement of compliance.
- Lot/batch no.: 1310049

DOSE FORMULATION
The dose formulations were made shortly before each dosing occasion using a magnetic stirrer, a spatula and/or an Ultra-Turrax (Janke & Kunkel, D-79219 Staufen) as homogenizers.
The test item was weighed into a tarred glass beaker on a suitable precision balance and the vehicle added (weight:volume).
Homogeneity of the test item in the vehicle was maintained during administration using a magnetic stirrer.
The test item was diluted in vehicle at a concentration of 0.2 g/ml and administered at a dosing volume of 10 ml/kg.

TREATMENT
The animals received a single dose of the test item by oral gavage administration at 2000 mg/kg body weight after being fasted for approximately 17 to 18 hours (access to water was permitted). Food was provided again approximately 3 hours after dosing.
The dosing volume was 10 ml/kg body weight.
Doses:
Single dose at 2000 mg/kg bw.
No. of animals per sex per dose:
3 females per group; two groups tested.
Control animals:
no
Details on study design:
OBSERVATIONS
- Duration of observation period following administration: 15 days
- Mortality / Viability: daily during the acclimatization period, during the first 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15.
- Body Weights: on test days 1 (prior to administration), 8 and 15.
- Clinical Signs: daily during the acclimatization period, during the first 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1. Once daily during days 2-15. All abnormalities were recorded.
- Necropsy: all animals were killed at the end of the observation period by Carbon dioxide asphyxiation and discarded after macroscopic examinations were performed. No organs or tissues were retained.
Statistics:
No statistical analysis was used.

Results and discussion

Effect levels
Sex:
female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Mortality:
No deaths occurred during the study.
Clinical signs:
other: Soft feces were recorded in one animal at the 3-hour observation. Otherwise, no clinical signs were observed during the course of the study.
Gross pathology:
No macroscopic findings were recorded at necropsy.

Any other information on results incl. tables

Mortality / Clinical Signs

Dose mg/kg bw Animal N. Sex Signs Test days
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0.5 1 2 3 5
2000 1 F No clinical signs √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
2 F No clinical signs √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
3 F No clinical signs √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
2000 4 F No clinical signs √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
5 F No clinical signs √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √
Soft feces √
6 F No clinical signs √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √

Key:  √ noted

* Examinations were performed within the first 30 minutes and 1, 2,3 and 5 hours after treatment.

No clinical signs were evident in any animal during the acclimatization period.

Macroscopical findings (scheduled necropsy, 21 May-08, day 15 after treatment)

Group 1:

Animal 1: no findings noted

Animal 2: no findings noted

Animal 3: no findings noted

Group 2:

Animal 4: no findings noted

Animal 5: no findings noted

Animal 6: no findings noted

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
The oral median lethal dose (LD50) of FAT 66042/A in female rat is greater than 2000 mg/kg body weight.
Executive summary:

An acute oral toxicity study in female Wistar rat was carried out with FAT 66042/A according to OECD guideline 423 and EU method B.1. Two groups, each of three female HanRcc:WIST (SPF) rats, were treated with test item by oral gavage administration at a dosage of 2000 mg/kg body weight. The test item was diluted in vehicle (PEG 300) at a concentration of 0.2 g/ml and administered at a dosing volume of 10 ml/kg.

The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs within the first 30 minutes and approximately 1, 2, 3 and 5 hours after treatment on day 1 and once daily during test days 2-15. Mortality / viability was recorded at approximately 30 minutes, 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15. All animals were necropsied and examined macroscopically. All animals survived until the end of the study period. Soft feces were recorded in one animal at the 3-hour observation. Otherwise, no clinical signs were observed during the course of the study. The body weight of the animals was within the range commonly recorded for this strain and age. No macroscopic findings were recorded at necropsy. The median lethal dose (LD50) of FAT 66042/A after single oral administration to female Wistar rats, observed over a period of 14 days is greater than 2000 mg/kg body weight.